To overcome the EGFR mutation‐induced immunosuppression, this work next develops F127ZIF‐8AB680, a pH‐responsive and tumor‐selective nanodrug specifically designed to target the CD73‐adenosine pathway within the acidic TME. Here, EGFR is linked to neoplasm.